Stevens-Johnson syndrome in HIV patients treated with nevirapine: Two case reports [7]

AIDS

Volumn 16, Issue 8, 2002, Pages 1197-1198

  Dodi, Ferdinando ^a   Alessandrini, Anna ^a   Camera, Marco ^a   Gaffuri, Lorenzo ^a   Morandi, Norberto ^a   Pagano, Gabriella ^a  

^a UNIVERSITY OF GENOA   (Italy)

Author keywords

[No Author keywords available]

Indexed keywords

BETAMETHASONE; CD4 ANTIGEN; EFAVIRENZ; ENALAPRIL; LAMIVUDINE; METHYLPREDNISOLONE; NELFINAVIR; NEVIRAPINE; RANITIDINE; RNA DIRECTED DNA POLYMERASE INHIBITOR; STAVUDINE; VIRUS RNA; ZIDOVUDINE;

ADULT; ANAPHYLACTOID PURPURA; ANTIBIOTIC PROPHYLAXIS; ANTIBIOTIC THERAPY; CASE REPORT; CHRONIC GASTRITIS; CLINICAL FEATURE; CRYOGLOBULINEMIA; DIFFERENTIAL DIAGNOSIS; DISEASE COURSE; DRUG MEGADOSE; DRUG WITHDRAWAL; HEPATITIS C; HIGHLY ACTIVE ANTIRETROVIRAL THERAPY; HUMAN; HUMAN IMMUNODEFICIENCY VIRUS INFECTION; HYPERTENSION; LETTER; LYMPHOCYTE COUNT; MALE; OPPORTUNISTIC INFECTION; PRIORITY JOURNAL; STEVENS JOHNSON SYNDROME; THROMBOCYTOPENIA; VIRUS LOAD;

ACQUIRED IMMUNODEFICIENCY SYNDROME; ADULT; ANTI-HIV AGENTS; HEPATITIS C, CHRONIC; HIV INFECTIONS; HUMANS; MALE; NEVIRAPINE; REVERSE TRANSCRIPTASE INHIBITORS; STEVENS-JOHNSON SYNDROME; SUBSTANCE ABUSE, INTRAVENOUS;

EID: 0037165907     PISSN: 02699370     EISSN: None     Source Type: Journal    
DOI: 10.1097/00002030-200205240-00022     Document Type: Letter

References (8)

1. Nevirapine-associated Stevens-Johnson syndrome
2. Safety profile of nevirapine, a nonnucleoside reverse transcriptase inhibitor for the treatment of human immunodeficiency virus infection
3. Nevirapine and rashes
4. Extrahepatic immunologic manifestations in chronic hepatitis C and hepatitis C virus serotypes
5. Thrombocytopenia associated with hepatitis C viral infection
6. Prednisone during the induction phase of nevirapine therapy appears to reduce the incidence of nevirapine-associated rash
7. Medication use and the risk of Stevens-Johnson syndrome or toxic epidermal necrolysis
8. Incidence of rash and discontinuation of nevirapine using two different escalating initial doses